You are here
Eyenovia Appoints Michael Rowe as Vice President of Marketing Ahead of Initiation of Multiple Phase III Programs
NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced the appointment of Michael Rowe as Vice President of Marketing.
Mr. Rowe is a veteran marketing professional with more than 20 years of experience in commercializing products and devices in the U.S. and globally across the healthcare industry. Prior to joining Eyenovia, Mr. Rowe was head of Global Strategic Marketing, Ophthalmology at Aerie Pharmaceuticals, Inc. where he was responsible for the U.S. and international commercialization, planning and execution for Rhopressa®, for the lowering of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Previously, he spent twelve years at Allergan plc in various roles supporting corporate strategic initiatives as well as strategic planning for the company’s worldwide glaucoma franchise, including the development of bimatoprost SR and the global launch of Ganfort® UD. Mr. Rowe also has held senior marketing roles at Bayer Healthcare Pharmaceuticals Inc., Women First Healthcare, Inc. and Pfizer Inc. Mr. Rowe holds an M.Sc. in Human Factors / Experimental Psychology from Rensselaer Polytechnic Institute and a B.A. in Psychology from the State University of New York at Stony Brook.
Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer commented, “We are excited to welcome Michael to the Eyenovia team as our Vice President of Marketing. As Eyenovia advances its late stage pipeline, we believe Michael can help us further develop our marketing strategy and focus our commercial efforts. We believe his extensive experience leading the strategic direction for the commercialization of various products at Aerie, Allergan and Bayer can help us realize our vision to transform the ophthalmic space.”
Mr. Rowe added, “I believe Eyenovia’s micro-therapeutic approach and diverse late stage pipeline has the ability to offer the field of ophthalmology a novel and sophisticated way to treat patients with front and back of the eye conditions. With the potential to commercialize two new products for mydriasis and dry eye in the next 18 months, as well as initiate phase III trials in myopia and chronic angle-closure glaucoma by mid-2019, I look forward to working with the team on developing and executing a robust commercialization plan that can help lead Eyenovia’s success.”
Eyenovia, Inc. (NASDAQ:EYEN) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases.
Forward Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the SEC. In addition, such statements could be affected by risks and uncertainties related to, among other things: our ability to attract and retain key personnel; our ability to develop and implement commercialization, marketing and manufacturing capabilities and strategies; risks involved in clinical trials, including, but not limited to, the initiation, timing, progress and results of such trials; the timing and our ability to submit applications for, obtain and maintain regulatory approvals for, our product candidates; the potential advantages of our product candidates; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; intellectual property risks; our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives; our expectations regarding our ability to fund our operating expenses and capital expenditure requirements; the impact of government laws and regulations; our competitive position; and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, we do not undertake any obligation to update any forward-looking statements.
Chief Financial Officer
The Ruth Group